Muscarinic Receptor Drugs are a class of pharmaceutical compounds that target muscarinic receptors, a type of receptor activated by the neurotransmitter acetylcholine. These drugs exert their therapeutic effects by modulating the activity of these receptors in various tissues and organs. They are utilized in the treatment of several medical conditions, including overactive bladder, chronic obstructive pulmonary disease (COPD), Parkinson's disease, gastrointestinal disorders, psychiatric disorders, and ophthalmic conditions. According to the World Health Organization (WHO), overactive bladder affects an estimated 33 million individuals in Europe and 33 million in the United States. COPD is a major cause of morbidity and mortality worldwide, with approximately 65 million people living with the condition in Europe and 16 million in the United States. Parkinson's disease, a neurodegenerative disorder, affects approximately 1.2 million individuals in Europe and 1 million in the United States, as reported by the WHO.
Growth drivers of the Muscarinic Receptor Drugs market include increasing prevalence and diagnosis rates of overactive bladder, COPD, and Parkinson's disease, advancements in drug development, the expanding aging population, and the strong presence of pharmaceutical companies with robust R&D pipelines and marketing capabilities. Companies such as Astellas, Gsk, Boehringer Ingelheim, Novartis, Almirall, Generic Mfg., Theravance Biopharma, Viatris, AstraZeneca, Cerevel Therap, Chiesi, Repurposed Therapy cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is currently conducting a clinical trial of the drug PT001 for the treatment of acute myelocytic leukemia.
Key Developments
- In September 2021, Boehringer Ingelheim launched Stiolto Respimat for Chronic obstructive pulmonary disease in France, Greece, Hungary, Portugal, Belgium, New Zealand, Israel, Germany, Sweden, Poland, Chile, Russia, Philippines, Netherlands, Czech Republic, Indonesia, Hong Kong, Argentina, Switzerland, Turkey, Mexico, Singapore, Ukraine
- In June 2023, GSK launched Anoro Ellipta for Chronic obstructive pulmonary disease in Italy.
Approved Muscarinic Receptor Drug Molecules.
- Vesicare (solifenacin)
- Tolterodine
- Fesoterodine
- Pilocarpine
- Tiotropium bromide dry powder inhaler
- Hyoscine butylbromide oral
- Ipratropium bromide
- Incruse Ellipta (umeclidinium)
- Spiriva Respimat (tiotropium bromide)
- Seebri Breezhaler (glycopyrronium bromide)
- Tudorza (aclidinium bromide)
- Hyoscine butylbromide injection
- Nefopam
- Yupelri (revefenacin)
- Oxybutynin transdermal
Muscarinic Receptor Drug Pipeline Molecules
- Glycopyrrolate (PT001)
- Batefenterol (GSK961081)
- Emraclidine (CVL-231)
- Glycopyrrolate inhalation (CHF 5259)
- Scopolamine intranasal (DPI-386)
- Pilocarpine low dose (CSF-1)
- Pirenzepine topical (WST-057)
- Darotropium bromide (GSK233705)
- Navafenterol (AZD8871)
- ASM-024
- GSK1034702
- HTL0016878
- HTL0018318
- Aceclidine (LNZ100)
- HTL0009936
- PSD506
Clinical Activity and Development of Muscarinic Receptor Drug
In the Muscarinic receptor drug space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,
- In Oct 2021, Orion completed the phase I FINDA trial Ultibro in Chronic obstructive pulmonary disease (In volunteers) in Finland.
- In April 2022, Chiesi Farmaceutici initiated enrolment in phase III trials of Riarify in Chronic obstructive pulmonary disease in Bulgaria, Hungary, and Poland
|
Product Name |
Total Studies |
|
Glycopyrrolate (PT001) |
19 |
|
Batefenterol (GSK961081) |
13 |
|
Emraclidine (CVL-231) |
12 |
|
Glycopyrrolate inhalation (CHF 5259) |
12 |
|
Scopolamine intranasal (DPI-386) |
12 |
|
Darotropium bromide (GSK233705) |
11 |
|
Navafenterol (AZD8871) |
5 |
|
ASM-024 |
4 |
|
GSK1034702 |
4 |
|
HTL0016878 |
4 |
|
HTL0018318 |
4 |
Target Indication Analysis of Muscarinic Receptor Drug
Muscarinic receptor drugs target muscarinic receptors, which are a subtype of acetylcholine receptors found in various tissues and organs throughout the body. These drugs are used for a wide range of indications, including the treatment of overactive bladder by reducing detrusor muscle contractions, managing chronic obstructive pulmonary disease (COPD) symptoms by dilating airways and reducing bronchoconstriction, and treating symptoms of Parkinson's disease by restoring the balance of acetylcholine and dopamine in the brain. Muscarinic receptor drugs also have potential applications in other conditions such as gastrointestinal disorders, psychiatric disorders, and ophthalmic conditions where modulation of cholinergic pathways is beneficial.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Muscarinic receptor drug drugs are used in the management of overactive bladder, COPD, Parkinson's disease, and other related disorders.
The growth drivers of the muscarinic receptor drugs market include increasing prevalence and diagnosis rates of overactive bladder, COPD, and Parkinson's disease, advancements in drug development, the expanding aging population, and the strong presence of pharmaceutical companies with robust r&d pipelines and marketing capabilities.
The major players in this space are Astellas, Gsk, Boehringer Ingelheim, Novartis, Almirall, Generic Mfg., Theravance Biopharma, Viatris, Astrazeneca, Cerevel Therap, Chiesi, Repurposed Therap, Sumitomo Pharma, Pari, Abbvie, Eli Lilly, Anavex, Endo, Astrazeneca, Pulmagen Therap, Orasis Pharma, Winsantor, Pulmagen Therap, Astrazeneca, Dong-A.
The market for muscarinic receptor drugs faces certain restraints, including limited selectivity and potential side effects due to non-specific targeting, as well as competition from alternative treatment options such as newer classes of medications or alternative therapies that may offer improved efficacy or safety profiles.
- Astellas
- Gsk
- Boehringer Ingelheim
- Novartis
- Almirall
- Generic Mfg.
- Theravance Biopharma, Viatris
- Astrazeneca
- Cerevel Therap
- Chiesi
- Repurposed Therap
- Sumitomo Pharma, Pari
- Abbvie
- Eli Lilly
- Anavex
- Endo
- Astrazeneca, Pulmagen Therap
- Orasis Pharma
- Winsantor
- Pulmagen Therap, Astrazeneca
- Dong-A